- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06798896
Renaissance 2: SPN-817 Phase 2, doppelblinde, placebokontrollierte Studie bei Erwachsenen mit fokalen Anfällen
Renaissance 2: Eine doppelblinde, randomisierte, placebokontrollierte, multizentrische, parallele Gruppenstudie zur Bewertung der Wirksamkeit, Sicherheit und Verträglichkeit von SPN-817 bei Erwachsenen mit Anfällen mit fokaler Beginn
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 administered as an adjunctive treatment in adults with focal onset seizures that have previously failed at least 2 anti-seizure medication (ASM) regimens. Participants will be taking 1 to 4 ASMs, with at least 4 seizures during the 6-week Screening Period. Following the Screening Period, eligible participants will be randomized 2:1 to SPN-817 (3.0-4.0 mg BID) or placebo and begin the Titration Period (8-10 weeks). In both treatment groups, open-label ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic adverse events [AEs]) will be taken (8 mg oral [PO]) prophylactically approximately 30 minutes before each study medication (SM) dose (ie, BID) during the Titration Period as an antiemetic. After the target dose of 3.0-4.0 mg BID is reached, participants will enter the Maintenance Period (14 weeks). Ondansetron (or another concomitant medication to assess pharmacological approaches to managing cholinergic AEs) may be taken as needed as either a preventative or therapeutic antiemetic during the Maintenance Period. Participants who complete the Maintenance Period will have the opportunity to enroll in a separate open-label study for continued treatment with SPN-817. Participants who do not enroll in the open-label study will undergo a Tapering Period (up to 4 weeks) and a follow-up safety phone call.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienkontakt
- Name: Navid Saeidi, MS
- Telefonnummer: 240-403-5328
- E-Mail: nsaeidi@supernus.com
Studieren Sie die Kontaktsicherung
- Name: Supernus Clinical Trials
- Telefonnummer: 240-403-5838
- E-Mail: clinicaltrials@supernus.com
Studienorte
-
-
Queensland
-
Herston, Queensland, Australien, 4029
- Rekrutierung
- Royal Brisbane and Women's Hospital
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Rekrutierung
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australien, 3168
- Rekrutierung
- Monash Medical Centre
-
Fitzroy, Victoria, Australien, 3065
- Rekrutierung
- St. Vincent's Hospital Melbourne
-
Melbourne, Victoria, Australien, 3004
- Rekrutierung
- The Alfred Hospital
-
Parkville, Victoria, Australien, 3052
- Rekrutierung
- Royal Melbourne Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Rekrutierung
- The Perron Institute for Neurological and Translational Science
-
-
-
-
-
Blagoevgrad, Bulgarien, 2700
- Rekrutierung
- Multiprofile Hospital for Active Treatment PULS
-
Pleven, Bulgarien, 5809
- Rekrutierung
- Medical Center (MC) Academica
-
Rousse, Bulgarien, 7012
- Rekrutierung
- Medical Center - Teodora EOOD
-
Sofia, Bulgarien, 1113
- Rekrutierung
- Multiprofile Hospital for Active Treatment in Neurology and Psychiatry "Sveti Naum" EAD
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bulgarien, 1431
- Rekrutierung
- University Multiprofile Hospital for Active Treatment Aleksandrovska, Clinic for Neurology Diseases
-
-
-
-
-
Lublin, Polen, 20-064
- Rekrutierung
- NZOZ NEUROMED M. and M. Nastaj Spółka Partnerska
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-727
- Rekrutierung
- Pratia MCM Kraków
-
-
Maloplski
-
Krakow, Maloplski, Polen, 30-363
- Rekrutierung
- Centrum Medyczne Plejady
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 01-684
- Rekrutierung
- Centrum Medyczne NeuroProtect
-
Warsaw, Masovian Voivodeship, Polen, 02-172
- Rekrutierung
- TZ Clinical Research powered by Pratia
-
Warsaw, Masovian Voivodeship, Polen, 02-952
- Rekrutierung
- Neurosphera
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Polen, 81-537
- Rekrutierung
- Synexus Polska Sp. z o. o. Oddział w Gdyni
-
Sopot, Pomeranian Voivodeship, Polen, 81-735
- Suspendiert
- Terra Centrum Leczenia
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polen, 40-123
- Rekrutierung
- NZOZ Wielospacjalistyczna Poradnia Lekarska Synapsis
-
Katowice, Silesian Voivodeship, Polen, 40-650
- Rekrutierung
- Novo-Med Zieliński i Wsp. Sp.J.
-
-
-
-
-
Budapest, Ungarn, 1125
- Rekrutierung
- Flash Clinic
-
Budapest, Ungarn, 1145
- Rekrutierung
- SE, Idegsebeszeti es Neurointervencios Klinika, Epilepszia Centrum
-
-
-
-
Arizona
-
Phoenix, Arizona, Vereinigte Staaten, 85004
- Rekrutierung
- Xenoscience
-
Phoenix, Arizona, Vereinigte Staaten, 85006
- Rekrutierung
- Banner University Medical Center-Phoenix
-
Tucson, Arizona, Vereinigte Staaten, 85724
- Rekrutierung
- University of Arizona College of Medicine - Tucson
-
Tucson, Arizona, Vereinigte Staaten, 85718
- Rekrutierung
- Center for Neurosciences
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72205
- Rekrutierung
- Clinical Trials, Inc
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Clinical Research Institute
-
Mission Hills, California, Vereinigte Staaten, 91345
- Rekrutierung
- Access Community Clinical Trials
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- University of California, Irvine
-
West Hills, California, Vereinigte Staaten, 91307
- Rekrutierung
- Focus Clinical Research
-
-
Connecticut
-
New Haven, Connecticut, Vereinigte Staaten, 06510
- Rekrutierung
- Yale University
-
-
Florida
-
Gulf Breeze, Florida, Vereinigte Staaten, 32561
- Rekrutierung
- Northwest Florida Clinical Research Group, LLC
-
Kissimmee, Florida, Vereinigte Staaten, 34744
- Rekrutierung
- Ilumina Medical Research
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami
-
Miami, Florida, Vereinigte Staaten, 33133
- Rekrutierung
- Visionary Investigators Network
-
Orlando, Florida, Vereinigte Staaten, 32806
- Beendet
- Research Institute of Orlando, LLC
-
Port Charlotte, Florida, Vereinigte Staaten, 33952
- Rekrutierung
- Medsol Clinical Research Center
-
Kontakt:
- Maria Vasconcelos, RN
- Telefonnummer: 941-623-9744
- E-Mail: mvasconcelos@medsolcrc.com
-
Port Saint Lucie, Florida, Vereinigte Staaten, 34990
- Rekrutierung
- Cleveland Clinic Florida Martin Health
-
-
Illinois
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40223
- Rekrutierung
- University of Louisville Physicians
-
-
Louisiana
-
Covington, Louisiana, Vereinigte Staaten, 70433
- Rekrutierung
- Neurocare of Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Suspendiert
- Ochsner Clinic Foundation
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins University
-
Bethesda, Maryland, Vereinigte Staaten, 20817
- Rekrutierung
- Mid Atlantic Epilepsy and Sleep Center
-
-
Michigan
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Rekrutierung
- Wayne State University - Detroit Medical Center
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Rekrutierung
- Northeast Regional Epilepsy Group - Hackensack
-
Neptune City, New Jersey, Vereinigte Staaten, 07753
- Rekrutierung
- Hackensack Meridian Health Jersey Shore University Medical Center
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- Rekrutierung
- Albany Medical Center
-
Amherst, New York, Vereinigte Staaten, 14226
- Rekrutierung
- Dent Neurologic Institute
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Northwell Health - Lenox Hill
-
Rochester, New York, Vereinigte Staaten, 14618
- Rekrutierung
- University of Rochester Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28806
- Rekrutierung
- Asheville Neurology Specialists
-
Charlotte, North Carolina, Vereinigte Staaten, 28211
- Rekrutierung
- OnSite Clinical Solutions, LLC
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Neurology Institute Epilepsy Center of Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
- Rekrutierung
- Thomas Jefferson University
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University Medical Center
-
-
Texas
-
El Paso, Texas, Vereinigte Staaten, 79912
- Rekrutierung
- Advanced Neurology Epilepsy and Sleep Center/ANESC Research
-
Frisco, Texas, Vereinigte Staaten, 75034
- Rekrutierung
- Stryde Research
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- UT Health Houston
-
-
Virginia
-
McLean, Virginia, Vereinigte Staaten, 22101
- Rekrutierung
- Medstar Health Research Institute
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of treatment-resistant focal epilepsy as adjudicated by the Epilepsy Study Consortium, Inc (ESCI);
- Failed to achieve sustained seizure freedom after ≥2 tolerated, appropriately chosen, and adequately dosed ASM drug schedules;
- Able to keep accurate Seizure electronic diaries [eDiaries] (with the aid of a caregiver as needed);
- Has a body mass index (BMI) between 18.0 and 40.0 kg/m2;
- Treatment with a stable dose of 1 to 4 current ASMs for ≥28 days prior to screening. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to Visit 1. The diet plan should be maintained throughout the duration of the study;
- At least 4 clinically observable focal onset seizures accepted by the ESCI prior to the first dose of SM (during the days of baseline Seizure electronic diary [eDiary] data collection) and no more than a consecutive 21-day period that was free of these seizures. To be eligible for the study, participants must comply with the eDiary on at least 80% of the days of baseline data collection;
Exclusion Criteria:
- Has taken huperzine A within the past 6 months;
- Prior diagnosis of combined focal and generalized epilepsy syndrome as evidenced by severe developmental delay and multiple seizure types and confirmed by electroencephalography (EEG) (eg, Lennox-Gastaut syndrome). Participants should also be excluded in case of nondiagnostic information;
- History of or current nonepileptic events that could be confused by the participant and/or study staff as epileptic seizures;
- Only has seizures that are difficult to count; for example, seizures that are not clinically observable;
- History of uncountable seizures, such as seizures that happen in a cluster that are too rapid to be counted individually;
- History of status epilepticus within 6 months prior to screening;
- Vagus nerve stimulation, deep brain stimulation, responsive neurostimulator system, or other neurostimulation for epilepsy device implanted or activated within 1 year prior to screening; or epilepsy surgery within 1 year prior to screening. Stimulation parameters for devices must have been stable for at least 3 months prior to Screening. Battery change for any epilepsy devices will be allowed; however, stimulation parameters must remain stable during the duration of the study;
- Any suicidal behavior or suicidal ideation related to item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS assessment in the 1 year before screening; a suicide attempt in the last 2 years before screening; or more than 1 lifetime suicide attempt;
- Chronic concomitant therapy with non-ASMs that have potent cholinergic (central or peripheral) or potent central (only) anticholinergic pharmacology.
- History of >2 allergic reactions to an ASM or 1 serious hypersensitivity reaction to an ASM;
- Any other reason which, in the opinion of the Investigator, would prevent the participant from taking part in the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: SPN-817
SPN-817, bid |
SPN-817 starting at 0.25 mg bid up to 4.00 mg bid |
|
Placebo-Komparator: Placebo
Placebo, bid |
Placebo, bid |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period
Zeitfenster: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Percent change in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Zeitfenster: Baseline and Maintenance Period (Maintenance Week 1-14)
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the 14 week Maintenance Period relative to baseline. |
Baseline and Maintenance Period (Maintenance Week 1-14)
|
|
PCH from baseline in focal onset seizure frequency per 28 days over the entire Treatment Period
Zeitfenster: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Percent change in 28-day frequency of focal seizures during the entire Treatment Period (Titration Period + Maintenance Period) relative to baseline |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Proportion of subjects experiencing ≥50% reduction in focal seizure frequency per 28 days from baseline
Zeitfenster: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
Greater than or equal to 50% reduction in 28-day frequency of focal seizures during the Treatment Period (Titration Period + Maintenance Period) relative to baseline. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Longest seizure-free interval over the entire Treatment Period
Zeitfenster: Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
The longest intervals in days between two seizures during the entire Treatment Period. |
Baseline through Titration Week 1 up to Week 10 and Maintenance Weeks 1-14
|
|
Incidence of treatment-emergent adverse events (TEAEs)
Zeitfenster: Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
The percent of subjects who took at least one dose of SPN-817 and reported at least one adverse event during SPN-817 treatment. |
Baseline through Titration Week 1 up to Week 10, Maintenance Weeks 1-14, and Tapering Period up to Week 4
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Maciej Gasior, MD, PhD, Supernus Pharmaceuticals, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 817P203
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .